Blog

The IPO market is more receptive than in previous years for HealthTech companies, driven by a renewed focus on profitability, strong business models and the ongoing digital transformation of healthcare.&nbsp; &nbsp;&nbsp; Companies like Doctolib and Pearsanta appear to be the most definitively positioned for a H2 2025 IPO based on their public statements and financial transparency or active underwriting processes.&nbsp; &nbsp;&nbsp; Others like Ro Health and Sword Health are strong contenders based on industry expert predictions and market dynamics. The actual timing for each company IPO will heavily depend on their final financial readiness and overall market conditions. &nbsp;&nbsp; Seven HealthTech IPO Candidates for H2 2025 &nbsp;&nbsp; Doctolib (Europe): This French-based company is consistently highlighted as a prime IPO candidate. They are a dominant online booking platform for medical appointments and provide practice management software across Europe. Their strong growth and stated aim for profitability in 2025 make them very attractive to public investors. Experts often compare them to the now-public Hinge Health in terms of market leadership within their respective segments.Pearsanta (Aditxt Subsidiary): This company is a particularly strong contender because of its publicly stated intentions. Focusing on early cancer detection, Pearsanta (a subsidiary of Aditxt) has engaged Dominari Securities for their IPO, with a targeted launch in H2 2025 to fund their commercialisation efforts for the Mitomic Technology Platform. This direct announcement lends significant weight to their IPO prospects.Ro Health: A prominent direct-to-consumer telehealth company that has diversified its offerings significantly (men's and women's health, weight management, dermatology, diagnostics). Having raised substantial capital, Ro is a frequently cited potential public market entrant as the telehealth sector matures and seeks clearer paths to profitability.Zocdoc: Another major player in online doctor appointment booking, primarily in the US market. With a large, established user base and a focus on improving operational efficiency for healthcare providers, an IPO is a logical next step when market conditions are seen as favourable.Aledade: This company is a leader in the shift towards value-based primary care, working with independent physician practices to improve outcomes and reduce costs. As the healthcare landscape continues to prioritize value over volume, Aledade's proven model and significant network make them a strong candidate.Quantum Health: A healthcare navigation and advocacy company that helps employees and their families navigate complex healthcare systems, often resulting in significant cost savings for employers and improved patient experiences. Their value proposition makes them appealing to investors.Sword Health: Operating in the digital musculoskeletal (MSK) care space, similar to Hinge Health, Sword Health offers virtual physical therapy and pain management solutions. Given the successful IPO of Hinge Health, Sword is often seen as the next logical company in this sub-sector to go public.<figure id="figure-n6n1trdv3mmdgjwrfw"><img id="n6n1trdv3mmdgjwrfw" src="https://cdn.durable.co/covers/3buB5PwhmCBG0afdaYjGCbfDfe7HsUD2tpPmzp3MKbVruujJ6UxSOtInVFDfOlUI.jpg" alt="" title="" class="object-cover bg-gray-100 rounded-2xl md:rounded-3xl lg:rounded-4xl" style="aspect-ratio: 1/1; object-position: center center;" data-corners="default" data-aspect="1:1" data-caption="" data-positionx="undefined" data-positiony="undefined" data-fullwidth="false" data-mce-src="https://cdn.durable.co/covers/3buB5PwhmCBG0afdaYjGCbfDfe7HsUD2tpPmzp3MKbVruujJ6UxSOtInVFDfOlUI.jpg" data-mce-style="aspect-ratio: 1/1; object-position: center center;"></figure>&nbsp; Why these companies are on the radar for H2 2025 &nbsp;&nbsp; Maturity and Scale: These companies are beyond the early startup phase, demonstrating significant market traction, substantial revenue, and often a large user/client base.Clear Path to Profitability (or already profitable): The market is increasingly demanding profitability or a very clear, short-term path to it. Many of these companies have either announced profitability goals for 2025 or are very close.Strong Value Proposition: They address critical pain points in healthcare (access, cost, chronic disease management, specialised care) with proven solutions.Strong Investor Backing: They have attracted significant venture capital and growth equity, indicating investor confidence in their long-term potential. These investors will be looking for an exit opportunity like an IPO.Market Tailwinds: Ongoing trends like the shift to value-based care, increasing adoption of telehealth, demand for personalised medicine, and the integration of AI continue to favour these types of healthtech innovators.Opening IPO Window: With some successful healthtech IPOs in H1 2025, market sentiment is improving, making H2 a more opportune time for companies ready to go public.Nelson Advisors &gt; Healthcare Technology M&amp;ANelson Advisors specialise in mergers, acquisitions &amp; partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.ukNelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis &amp; predictions @ https://www.healthcare.digital&nbsp;We share our views on the latest Healthcare Technology mergers, acquisitions &amp; partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb&nbsp;Founders for Founders &gt; We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSideNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NTContact Us<a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>Meet UsDigital Health Rewired &gt; 18-19th March 2025 &gt; Birmingham, UKNHS ConfedExpo &nbsp;&gt; 11-12th June 2025 &gt; Manchester, UKHLTH Europe &gt; 16-19th June 2025, Amsterdam, NetherlandsHIMSS AI in Healthcare &gt; 10-11th July 2025, New York, USAWorld Health Summit 2025 &gt; October 12-14th 2025, Berlin, GermanyHLTH USA 2025 &gt; October 18th-22nd 2025, Las Vegas, USAMEDICA 2025 &gt; November 11-14th 2025, Düsseldorf, Germany

7 HealthTech IPO Candidates for H2 2025: Doctolib, Pearsanta, Ro Health, Zocdoc, Aledade, Quantum Health, Sword Health

The HealthTech M&amp;A market is dynamic, with increased activity in distressed assets and a focus on strategic acquisitions, especially in AI-driven care and data analytics. Valuations are moderating but still vary significantly by sub-sector and company profile.&nbsp; &nbsp;&nbsp; To significantly increase the chances of a successful merger or acquisition, Nelson Advisors recommend HealthTech founders focus on the following key areas: &nbsp;&nbsp; 1. Proactive Preparation &amp; Data Excellence &nbsp;&nbsp; Invest in Data Infrastructure Early: Organizations with established data capabilities before pursuing deals achieve significantly better M&amp;A outcomes. This means having robust data governance, quality, security, and regulatory compliance (e.g., HIPAA, GDPR) embedded from the outset.Comprehensive Data Analytics: Go beyond traditional financial metrics. Systematically gather and analyse data on clinical outcomes, operational efficiency, cultural compatibility, and technological maturity. Predictive modelling of future revenue, regulatory risks, and market conditions can reduce valuation uncertainty.Cross-Domain Analytics: The most valuable insights emerge from connecting financial, clinical, operational, and technological data, rather than analysing domains in isolation.Detailed Documentation &amp; Cleanliness: Ensure all aspects of your company – legal, commercial, financial, HR, and technical – are meticulously documented and readily available. This includes organizational charts, contracts, financial statements, IP agreements, and compliance records. Any "skeletons in the closet" will likely be uncovered during due diligence and can derail a deal.&nbsp; 2. Strong Financial &amp; Commercial Foundations &nbsp;&nbsp; Demonstrate Clear Value: Clearly articulate your value proposition, market fit, and how your technology addresses significant healthcare challenges. Highlight strong financial performance (revenue, growth, profitability), a large and engaged user base, and clear market traction.Sustainable Business Model: Show consistent revenue growth and strong gross margins. Buyers are increasingly cautious and focused on profitability. Companies with lower customer acquisition costs (CACs) are also highly valued.Strategic Alignment: Understand what strategic buyers are looking for (e.g., technology that plugs portfolio gaps like AI diagnostics or patient management tools). Position your company as a clear strategic fit for potential acquirers.Realistic Valuation Expectations: Be prepared for potentially lower multiples, especially if your company is distressed. While AI-driven diagnostics might still command premium appeal, overall sector valuations are moderating. Understand the specific valuation multiples for your HealthTech sub-sector.3. Robust Technology &amp; Intellectual Property &nbsp;&nbsp; Thorough Technology Due Diligence (TDD) Readiness: Technology is a critical asset. Be ready for a deep dive into your software, IT infrastructure, cybersecurity, data privacy practices, and intellectual property. Address any potential issues like technical debt, security vulnerabilities, or IP disputes proactively.Scalability and Interoperability: Buyers will assess your technology's ability to scale and integrate with their existing systems. Healthcare technology involves complex systems and diverse data formats (e.g., EHRs), so demonstrating interoperability is crucial.Strong IP Portfolio: Companies with valuable intellectual property (patents, trademarks, proprietary code) are typically valued at a higher multiple. Ensure clear ownership and protection of your IP.AI and SaMD Specifics: If your company is in Software as a Medical Device (SaMD) or AI as a Medical Device (AIaMD), emphasise strong in-house clinical expertise, the quality and alignment of your evidence (studies on final products, not prototypes), and a clear understanding of the clinical context for your product. Be ready to demonstrate adequate budgets and timelines for product development, QMS, V&amp;V testing, and regulatory submissions.4. Operational Excellence &amp; Talent Management &nbsp;&nbsp; Operational Efficiency: Show strong operational metrics like staff retention rates, technology integration milestones, and process efficiency improvements.Talent Retention: Acquirers often value the talent within a company. Foster a strong company culture, invest in your employees, and minimise key person risk by developing a strong leadership team.Clear Roles and Responsibilities: A well-structured organisation with clear roles and responsibilities makes integration smoother.Cultural Compatibility: Proactively address potential cultural integration. Misaligned cultures are a significant reason M&amp;A deals fail.5. Regulatory Compliance &amp; Risk Mitigation &nbsp;&nbsp; Rigorous Compliance: Healthcare is highly regulated. Ensure your company adheres to all relevant healthcare regulations (HIPAA, GDPR, etc.) from the outset. Be prepared for increased regulatory scrutiny in areas like data privacy and antitrust.Compliance Integration Planning: Anticipate and plan for the complexities of integrating compliance frameworks. Discovering significant compliance gaps during due diligence can deter acquirers.Risk Management: Identify and mitigate potential risks early. This includes financial liabilities, unsustainable business models, cybersecurity vulnerabilities, and regulatory non-compliance.6. Strategic Planning for Integration &nbsp;&nbsp; Start Integration Planning Early: Comprehensive integration planning should begin during due diligence, not after closing the deal. This includes technology, personnel, and processes.Leadership &amp; Governance: Appoint integration leaders and set a clear governance framework with defined decision-making processes.Communication: Maintain open and transparent communication with all stakeholders throughout the process.&nbsp; In today's cautious market, buyers are focusing heavily on value and profitability, and are less willing to overpay. Therefore, HealthTech founders who can clearly demonstrate strong fundamentals, mitigate risks, and show a clear path to successful integration will significantly enhance their chances of a successful M&amp;A closing. &nbsp;Nelson Advisors &gt; Healthcare Technology M&amp;A &nbsp;Nelson Advisors specialise in mergers, acquisitions &amp; partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk &nbsp; &nbsp; Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis &amp; predictions @ https://www.healthcare.digital&nbsp; &nbsp;&nbsp; We share our views on the latest Healthcare Technology mergers, acquisitions &amp; partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb&nbsp; &nbsp;&nbsp; Founders for Founders &gt; We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk &nbsp;#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide &nbsp;&nbsp; Nelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NT &nbsp;&nbsp; Contact Us &nbsp;&nbsp; <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a> Meet Us &nbsp; Digital Health Rewired &gt; 18-19th March 2025 &gt; Birmingham, UK &nbsp; NHS ConfedExpo &nbsp;&gt; 11-12th June 2025 &gt; Manchester, UK &nbsp; HLTH Europe &gt; 16-19th June 2025, Amsterdam, Netherlands &nbsp; HIMSS AI in Healthcare &gt; 10-11th July 2025, New York, USA &nbsp; World Health Summit 2025 &gt; October 12-14th 2025, Berlin, GermanyHLTH USA 2025 &gt; October 18th-22nd 2025, Las Vegas, USAMEDICA 2025 &gt; November 11-14th 2025, Düsseldorf, Germany

What can HealthTech founders do to significantly increase the chances of their merger or acquisition closing in today's market?

European Healthcare Technology M&A: Valuation Multiples and Market Dynamics Report by Nelson Advisors

chatEHR: The Future of Clinical Conversations Enabled by Software, AI and Machine Learning

Ambient Voice Technology and the NHS 10 Year Plan: Strategy, Future Applications, Key Suppliers, Funding and Regulatory Landscape

Healthcare Web Browser to train AI models: Next Billion Dollar HealthTech Company

Nelson Advisors

Healthcare Technology > Mergers, Acquisitions, Growth, Strategy, Investments

EB Garamond

Nelson Advisors

Blog

7 HealthTech IPO Candidates for H2 2025: Doctolib, Pearsa...

What can HealthTech founders do to significantly increase...

European Healthcare Technology M&A: Valuation Multiples a...

chatEHR: The Future of Clinical Conversations Enabled by ...

Ambient Voice Technology and the NHS 10 Year Plan: Strate...

Healthcare Web Browser to train AI models: Next Billion D...